Eyenovia to Present Phase 3 Clobetasol Study Results at AAO 2024 Expo

Eyenovia, Inc., a company specializing in ophthalmic technology, has announced the presentation of the findings from its successful Phase 3 study of clobetasol propionate suspension 0.05% at the American Academy of Ophthalmology (AAO) 2024 Expo, which will take place from October 19 to 21 in Chicago. This study, known as CPN-302, paved the way for the FDA approval of clobetasol as an effective treatment for pain and inflammation following ocular surgery. The product was launched and became commercially available in the United States on September 26, 2024.

Michael Rowe, the Chief Executive Officer of Eyenovia, expressed his pleasure at seeing the Phase 3 study results presented at the AAO Expo. He highlighted that the study demonstrated significant and rapid relief from pain and inflammation as early as four days post-surgery compared to a placebo. Additionally, the results showed a quicker improvement in visual acuity and a favorable safety profile.

Clobetasol is now accessible through Eyenovia's pharmacy partner, Medvantx, or via EyenoviaRx.com, offering a convenient twice-daily dosing regimen that aims to streamline the process for prescribers. Rowe believes that clobetasol is well-positioned to become a preferred post-operative steroid for both physicians and patients due to its efficacy and ease of distribution.

The presentation, titled "Clobetasol Propionate Ophthalmic Suspension 0.05% (APP 13007) for the Treatment of Postsurgical Inflammation and Pain (Study CPN-302)," will be delivered by Dr. Jeffrey H. Levenson of Levenson Eye Associates and will be available on-demand throughout the AAO Expo.

Eyenovia, Inc. is an ophthalmic technology company developing innovative products using its Optejet platform. The company's focus includes the commercialization of Mydcombi® for mydriasis and clobetasol propionate ophthalmic suspension, 0.05% for post-surgical pain and inflammation. Additionally, Eyenovia is working on late-stage development of treatments for pediatric progressive myopia using the Optejet device and pursuing out-licensing opportunities for other indications.

For more information about Eyenovia and its products, visit Eyenovia.com.